<DOC>
	<DOCNO>NCT00388349</DOCNO>
	<brief_summary>Phase II Gemcitabine + HD Chemotherapy Followed PBSC Rescue HD</brief_summary>
	<brief_title>Gemcitabine Hodgkin 's Disease Chemotherapy Followed Peripheral Blood Stem Cell Rescue Hodgkin 's Disease</brief_title>
	<detailed_description>To assess non-hematologic toxicity determine phase II dose gemcitabine combination vinorelbine follow carmustine , etoposide cyclophosphamide autologous hematopoietic stem cell transplantation .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<criteria>Histologically proven recurrent refractory Hodgkin 's lymphoma review Stanford University Medical Center . The diagnosis make excisional biopsy whenever possible . Biopsy refractory recurrent disease prefer fine needle aspirate supportive morphology immunohistochemistry acceptable recurrent persistent galliumpositive positron emission tomography ( PET ) positive radiographic disease major surgery would require . Age &lt; 70 year ECOG performance status 03 . One adverse risk factor Phase I study : stage IV extranodal disease relapse `` B '' symptom failure achieve minimal disease recent chemotherapy ( single lymph node &lt; 2 cm &gt; 75 % reduction bulky tumor mass bone marrow involvement &lt; 10 % ) progression induction salvage therapy . Patients eligible regardless risk factor Phase II study . Computerized tomography scan chest , abdomen pelvis within 4 week registration . Assessment response last chemotherapy prior registration mandatory . Gallium scan PET scan determination disease within 4 week registration highly recommend . Bone marrow biopsy cytogenetic analysis within 8 week registration Women childbearing potential sexually active male strongly advise use accept effective method birth control . Patients must pretreatment serum bilirubin &lt; 2 x institutional ULN , serum creatinine &lt; 2 x institutional ULN measure estimate creatinine clearance &gt; 60 cc/min follow formula ( test must perform within 28 day prior registration ) : Estimated Creatinine Clearance = ( 140 age ) X WT ( kg ) X 0.85 female X creatinine ( mg/dl ) Patients must EKG within 42 day prior registration show significant abnormality suggestive active cardiac disease . Patients age 50 , receive chest irradiation total 300 mg/m2 doxorubicin , history cardiac disease must radionuclide ejection fraction within 42 day registration . If ejection fraction 4050 % , patient cardiology consult . Patients must correct diffusion capacity &gt; 55 % . Patients must inform investigational nature study must sign give write informed consent accordance institutional federal guideline . Patients know human immunodeficiency virus ( HIV ) positive concern opportunistic infection hematologic reserve consider significantly great population . The antibody test HIV must perform within 42 day registration . No chemotherapy corticosteroid administer within 2 week initiation protocol therapy . Pregnant breastfeed woman due know birth defect association treatment use study . Patients require therapy coronary artery disease , cardiomyopathy , dysrhythmia , congestive heart failure . Patients age 50 , receive chest irradiation total 300 mg/m^2 doxorubicin , history cardiac disease must radionuclide ejection fraction within 42 day registration . If ejection fraction &lt; 40 % patient eligible . Patients know allergy etoposide history Grade 3 hemorrhagic cystitis cyclophosphamide . Patients &gt; grade 2 sensory motor peripheral neuropathy prior vinca alkaloid use . No prior malignancy allow except adequately treat basal cell squamous cell skin cancer , situ cervical cancer cancer patient diseasefree five year . Patients prior diagnosis nonHodgkin 's lymphoma eligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>